Wachtell, Goodwin Rep In Regeneron's $250M Biopharma Buy
Regeneron Pharmaceuticals Inc., guided by Wachtell Lipton Rosen & Katz, said Tuesday it is buying Goodwin Procter LLP-advised clinical-stage Checkmate Pharmaceuticals Inc. for $250 million....To view the full article, register now.
Already a subscriber? Click here to view full article